ALLO Stock Overview
A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Allogene Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.12 |
| 52 Week High | US$5.78 |
| 52 Week Low | US$2.01 |
| Beta | 0.84 |
| 11 Month Change | -24.29% |
| 3 Month Change | -18.15% |
| 1 Year Change | -22.06% |
| 33 Year Change | -88.64% |
| 5 Year Change | -92.45% |
| Change since IPO | -91.52% |
Recent News & Updates
Recent updates
Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
Aug 27Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Jun 12We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
May 30
Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Apr 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Mar 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Jun 09We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Feb 22Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans
Oct 27Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate
Oct 06An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued
Sep 22Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A
Sep 13Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M
Aug 09Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
Jul 14Allogene Therapeutics: Multibagger Potential, But Terribly Risky
Jun 24Shareholder Returns
| ALLO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -22.1% | -7.5% | -1.2% |
| 1Y | -22.1% | 14.1% | 30.4% |
Return vs Industry: ALLO underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: ALLO underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| ALLO volatility | |
|---|---|
| ALLO Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALLO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALLO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 233 | David Chang | www.allogene.com |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia.
Allogene Therapeutics, Inc. Fundamentals Summary
| ALLO fundamental statistics | |
|---|---|
| Market cap | US$444.50m |
| Earnings (TTM) | -US$283.43m |
| Revenue (TTM) | US$43.00k |
Over9,999x
P/S Ratio-1.6x
P/E RatioIs ALLO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALLO income statement (TTM) | |
|---|---|
| Revenue | US$43.00k |
| Cost of Revenue | US$201.99m |
| Gross Profit | -US$201.94m |
| Other Expenses | US$81.48m |
| Earnings | -US$283.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.35 |
| Gross Margin | -469,639.53% |
| Net Profit Margin | -659,137.21% |
| Debt/Equity Ratio | 0% |
How did ALLO perform over the long term?
See historical performance and comparison